Banner
What Next For Messenger RNA (mRNA)? Maybe Inhalable Vaccines

No one likes getting a needle but most want a vaccine. A new paper shows progress for messenger...

Toward A Single Dose Smallpox And Mpox Vaccine With No Side Effects

Attorney Robert F. Kennedy Jr. and his US followers over the last 25 years have staunchly opposed...

ChatGPT Is Cheaper In Medicine And Does Better Diagnoses Even Than Doctors Using ChatGPT

General medicine, routine visits and such, have gradually gone from M.D.s to including Osteopaths...

Even After Getting Cancer, Quitting Cigarettes Leads To Greater Longevity

Cigarettes are the top lifestyle risk factor for getting cancer, though alcohol and obesity have...

User picture.
News StaffRSS Feed of this column.

News Releases From All Over The World, Right To You... Read More »

Blogroll
Each year millions of infants, toddlers and preschool children require anesthesia or sedation for various procedures and a new review suggest caution about their use.

A team of anesthesiology investigators and toxicologists writing in the New England Journal of Medicine reviewed existing animal and human studies for the impact of anesthetics on developing brains. 

Observational studies of children have been weak, but they still suggested a correlation between children who had received anesthetics and long-term cognitive impairments such as learning disabilities. Children between the ages of one and three appeared to be at a higher risk of adverse effects.
Wheat is a critical staple crop that provides 20% of the calories and over 25% of the protein consumed by humans.

'Yellow rust' caused by the fungus Puccinia striiformis f. sp. tritici (PST) is one of the plant's major diseases and is found throughout the major wheat-producing areas of the world. Infections lead to significant reductions in both grain quality and yield, with some rare events leading to the loss of an entire crop. New strains of the fungus have recently emerged that adapt to warmer temperatures.
The MUSE instrument on ESO's Very Large Telescope has given astronomers the best ever 3-D view of the deep Universe - in just 27 hours.

By taking very long exposure pictures of regions of the sky, astronomers have created many deep fields that have revealed much about the early Universe. The most famous of these was the original Hubble Deep Field, taken by the NASA/ESA Hubble Space Telescope over several days in late 1995. This spectacular and iconic picture rapidly transformed our understanding of the content of the Universe when it was young. It was followed two years later by a similar view in the southern sky -- the Hubble Deep Field South. 
A pre-clinical study of ANAVEX 2-73 found that it prevents mitochondrial dysfunction and blocks resulting oxidative stress and apoptosis (cell death) in a nontransgenic mouse model of Alzheimer's disease (AD).

Mitochondrial damages have been consistently reported as an early cause of Alzheimer's disease and appear before amyloid-beta plaques and memory decline in Alzheimer's patients and transgenic mice. If so, by preserving mitochondrial functionality and reducing other key Alzheimer's disease hallmarks, it has the potential to prevent, stop, slow or reverse the disease, in addition to treating its symptoms.
The use of animals in experimental research has soared at US laboratories, according to People for the Ethical Treatment of Animals (PETA), and taxpayer-funded scientists are the culprits.

The 25 largest recipients of government funding increased animal experimentation 73 percent in 15 years, despite growing public opposition to the practice and mounting evidence that animal studies often do not faithfully translate to people, they write.

They also say the data contradict government claims of reduced animal use and are at odds with government policies designed to curb and replace the use of animals in experiments. 

Palbociclib, an investigational oral medication that works by blocking molecules responsible for cancer cell growth, is well tolerated and extends progression-free survival (PFS) in newly diagnosed, advanced breast cancer patients, including those whose disease has stopped responding to traditional endocrine treatments. Results of the phase II study, led by researchers in the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania , were published this month in Clinical Cancer Research. Earlier phase I results by researchers at Penn Medicine contributed to the development of palbociclib, which was recently approved by the U.S. Food and Drug Administration (FDA) for metastatic breast cancer patients just beginning to undergo endocrine therapy.